Abstract
Pathological high-frequency oscillations (HFOs 80-600 Hz) in intracranial EEG distinguish epileptogenic cortex. However, it is uncertain whether utilizing HFO measures for surgical planning improve epilepsy surgery seizure outcomes and minimize morbidity. The clinical gold standard for planning an epilepsy surgery involves consensus between epileptologists, radiologists, and neurosurgeons based on multimodality findings, and particularly the location of the seizure onset zone. We asked whether seizure freedom following epilepsy surgery could be accurately predicted using machine learning that uses measures of HFO features relative to the boundaries of a surgical resection or laser ablation. We detected and quantified HFOs from depth EEG contacts during 30-200 minutes of non-rapid eye movement sleep from 78 pre-surgical patients from three institutions. We trained a three-branch convolutional neural network (CNN) using 3 neuroanatomic features and 37 HFO derived features. The first and second CNN branches computed within and between patient differences, respectively, and the third branch contains the resected contacts that also influenced branches 1 and 2. We found that this HFO CNN labeled the seizure free patients with 92% accuracy using 5-fold cross-validation. These results suggest that a resection planned with the clinical gold standard can be prospectively evaluated by a HFO CNN approach to test whether the resection boundaries will achieve a seizure free outcome. Future work will explore utilizing the HFO CNN approach for counterfactual virtual resections constrained by a utility function to minimize morbidity.
Competing Interest Statement
M.R.S. has received compensation for speaking at continuing medical education (CME) programmes from Medscape, Projects for Knowledge, International Medical Press and Eisai. He has consulted for Medtronic, Neurelis and Johnson & Johnson. He has received research support from Eisai, Medtronic, Neurelis, SK Life Science, Takeda, Xenon, Cerevel, UCB Pharma, Janssen and Engage Pharmaceuticals. He has received royalties from Oxford University Press and Cambridge University Press. The remainder of the authors declare no competing interests.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Jefferson University gave ethical approval for this work IRB of University of California Los Angeles gave ethical approval for this work IRB of Zhejiang University gave ethical approval for this work IRB of Stony Brook University deemed this work IRB exempt
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
